UKONIQ
Total Payments
$16.5M
Transactions
7,392
Doctors
945
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $209,606 | 103 | 0 |
| 2023 | $3.2M | 1,123 | 0 |
| 2022 | $6.7M | 2,747 | 375 |
| 2021 | $6.5M | 3,419 | 678 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.2M | 6,076 | 98.0% |
| Consulting Fee | $224,266 | 138 | 1.4% |
| Food and Beverage | $44,672 | 1,109 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,148 | 15 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $22,254 | 8 | 0.1% |
| Travel and Lodging | $10,632 | 42 | 0.1% |
| Education | $45.44 | 4 | 0.0% |
Payments by Type
Research
$16.2M
6,076 transactions
General
$332,017
1,316 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) | TG Therapeutics, Inc. | $7.1M | 0 |
| A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | TG Therapeutics, Inc. | $2.6M | 0 |
| UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkins Lymphoma | TG Therapeutics, Inc. | $2.0M | 0 |
| UTX-TGR-203: A Phase II Study Evaluation the Safety and Efficacy of umbralisib (TGR-1202) in combination with ublituxaimb in Patients with Treatment Nave Follicular Lymphoma and Small Lymphocytic Lymphoma | TG Therapeutics, Inc. | $1.2M | 0 |
| An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304 | TG Therapeutics, Inc. | $773,333 | 0 |
| Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | TG Therapeutics, Inc. | $599,690 | 0 |
| A Phase 2 Study of Acalabrutinib, Umbralisib and Ublituximab in Relapsed and Previously Untreated CLL Patients | TG Therapeutics, Inc. | $459,304 | 0 |
| Extension Trial of Ublituximab and Umbralisib (TGR-1202) in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | TG Therapeutics, Inc. | $329,949 | 0 |
| Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | TG Therapeutics, Inc. | $305,688 | 0 |
| A Phase 2 Study to Assess the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Parameters of Umbralisib in Treatment Nave Patients with Chronic Lymphocytic Leukemia (CLL) | TG Therapeutics, Inc. | $209,625 | 0 |
| A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies | TG Therapeutics, Inc. | $136,805 | 0 |
| A Phase 2 Study of Acalabrutinib and PI3K inhibitor Umbralisib in Combination with Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma | TG Therapeutics, Inc. | $103,252 | 0 |
| Evaluate the Efficacy and Safety of TGR-1202 (Umbralisib) in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | TG Therapeutics, Inc. | $100,784 | 0 |
| Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma | TG Therapeutics, Inc. | $79,011 | 0 |
| Phase I study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refractory CLL or Richters transformation of CLL | TG Therapeutics, Inc. | $73,832 | 0 |
| Ublituximab as initial therapy for treatment nave follicular or marginal zone lymphoma with response-driven addition of umbralisib for suboptimal response | TG Therapeutics, Inc. | $62,253 | 0 |
| A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients with Follicular Lymphoma and Marginal Zone Lymphoma | TG Therapeutics, Inc. | $48,480 | 0 |
| UTX-TGR-203: A Phase II Study Evaluation the Safety and Efficacy of umbralisib (TGR-1202) in combination with ublituximab in Patients with Treatment Nave Follicular Lymphoma and Small Lymphocytic Lymphoma_IIT | TG Therapeutics, Inc. | $29,540 | 0 |
| A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the combination of Pembrolizumab with TGR-1202 in patients with relapsed/refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL) | TG THERAPEUTICS, INC. | $21,390 | 0 |
| ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) | TG THERAPEUTICS, INC. | $18,700 | 0 |
Top Doctors Receiving Payments for UKONIQ — Page 37
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Columbia, MO | $13.66 | 1 |
| , MBBS | Hematology & Oncology | Columbia, MO | $13.66 | 1 |
| , D.O | Internal Medicine | Columbia, MO | $13.66 | 1 |
| , CRNP | Family | Columbia, MD | $13.56 | 1 |
| Jaclyn Hulett | Family | Sioux City, IA | $13.49 | 1 |
| , M.D | Hematology & Oncology | Sioux City, IA | $13.49 | 1 |
| Nasser Abu-Erreish | — | Sioux City, IA | $13.49 | 1 |
| , NP | Family | Binghamton, NY | $13.38 | 1 |
| , N.P | Family | Johnson City, NY | $13.37 | 1 |
| , NP-C | Adult Health | Berkshire, NY | $13.37 | 1 |
| , D.O | Hematology & Oncology | Azle, TX | $13.37 | 1 |
| , MD | Hematology | Franklin Lakes, NJ | $13.25 | 1 |
| , M.D | Internal Medicine | Jacksonville, FL | $13.25 | 1 |
| , APRN | Adult Health | Jacksonville, FL | $13.25 | 1 |
| , D.O | Internal Medicine | Jacksonville, FL | $13.25 | 1 |
| , FNP | Nurse Practitioner | Yorktown Heights, NY | $13.05 | 1 |
| , MD | Hematology & Oncology | Jersey City, NJ | $13.02 | 1 |
| , MD | Hematology & Oncology | Jersey City, NJ | $13.02 | 1 |
| , MD | Medical Oncology | Austin, TX | $12.94 | 1 |
| , MD | Medical Oncology | Monroeville, AL | $12.93 | 1 |
| , M.D | Medical Oncology | Lexington, KY | $12.71 | 1 |
| , M.D | Hematology & Oncology | Rogers, AR | $12.70 | 1 |
| , M.D | Hematology & Oncology | Springdale, AR | $12.70 | 1 |
| , APRN | Family | Rogers, AR | $12.70 | 1 |
| , PA-C | Physician Assistant | Rogers, AR | $12.70 | 1 |
Ad
Manufacturing Companies
- TG Therapeutics, Inc. $16.3M
- TG THERAPEUTICS, INC. $294,836
Product Information
- Type Drug
- Total Payments $16.5M
- Total Doctors 945
- Transactions 7,392
About UKONIQ
UKONIQ is a drug associated with $16.5M in payments to 945 healthcare providers, recorded across 7,392 transactions in the CMS Open Payments database. The primary manufacturer is TG THERAPEUTICS, INC..
Payment data is available from 2021 to 2024. In 2024, $209,606 was paid across 103 transactions to 0 doctors.
The most common payment nature for UKONIQ is "Unspecified" ($16.2M, 98.0% of total).
UKONIQ is associated with 20 research studies, including "ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL)" ($7.1M).